Relatlimab

From WikiMD.org
Jump to navigation Jump to search

Relatlimab

Relatlimab (pronunciation: reh-lat-li-mab) is a novel immunotherapy drug currently under investigation for its potential use in the treatment of melanoma, a type of skin cancer. It is a fully human monoclonal antibody that targets the lymphocyte-activation gene 3 (LAG-3), a protein found on the surface of immune cells.

Etymology

The name "Relatlimab" is derived from the International Nonproprietary Names (INN) system for pharmaceutical substances. The "-limab" suffix is used for human monoclonal antibodies, while the prefix "Relat-" is unique to the drug itself.

Mechanism of Action

Relatlimab works by binding to the LAG-3 protein on T cells, a type of white blood cell that plays a crucial role in the immune response. By blocking LAG-3, Relatlimab enhances T cell function and promotes an immune response against cancer cells.

Clinical Trials

Relatlimab is currently being evaluated in clinical trials for its safety and efficacy in treating patients with melanoma. These trials are exploring the use of Relatlimab in combination with other immunotherapy drugs, such as nivolumab, a PD-1 inhibitor.

Related Terms

  • Immunotherapy: A type of cancer treatment that uses the body's immune system to fight cancer.
  • Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
  • T cells: A type of white blood cell that is of key importance to the immune system and is at the core of adaptive immunity.
  • Nivolumab: A medication used to treat a number of types of cancer. This drug is a type of immunotherapy.

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski